ABBVIE ($ABBV) posted quarterly earnings results for Q4 2025 on Wednesday, February 4th. The company reported earnings of $2.71 per share, beating estimates of $2.71 by $0.00. The company also reported revenue of $16,618,000,000, missing estimates of $16,748,937,999 by $-130,937,999.
You can see Quiver Quantitative's $ABBV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ABBVIE Insider Trading Activity
ABBVIE insiders have traded $ABBV stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- AZITA SALEKI-GERHARDT (EVP, CHIEF OPERATIONS OFFICER) sold 42,370 shares for an estimated $8,407,055
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ABBVIE Hedge Fund Activity
We have seen 1,777 institutional investors add shares of ABBVIE stock to their portfolio, and 1,727 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 10,559,645 shares (+72.3%) to their portfolio in Q3 2025, for an estimated $2,444,980,203
- WELLINGTON MANAGEMENT GROUP LLP added 8,646,424 shares (+457.4%) to their portfolio in Q3 2025, for an estimated $2,001,993,012
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC removed 3,134,454 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $725,751,479
- VANGUARD GROUP INC added 3,032,438 shares (+1.7%) to their portfolio in Q4 2025, for an estimated $692,881,758
- CAPITAL INTERNATIONAL INVESTORS removed 2,947,890 shares (-21.6%) from their portfolio in Q3 2025, for an estimated $682,554,450
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,830,775 shares (-53.6%) from their portfolio in Q3 2025, for an estimated $423,897,643
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,797,129 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $410,626,005
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ABBVIE Government Contracts
We have seen $398,667 of award payments to $ABBV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- IMPLANT: $35,788
- 4567253744!NATRELLE TE SMOOTH 133S-SV-13-T: $33,629
- PROSTHETIC ORDER - IMPLANT ITEMS: $15,758
- PROSTHETIC ORDER - BREAST IMPLANTS: $14,124
- 4567881995!NATRELLE TE SMOOTH 133S-MV-15-T: $13,170
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ABBVIE Congressional Stock Trading
Members of Congress have traded $ABBV stock 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON has traded it 3 times. They made 0 purchases and 3 sales worth up to $45,000 on 12/18, 11/13, 08/14.
- REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
- SENATOR JOHN BOOZMAN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 08/22, 08/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ABBVIE Analyst Ratings
Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HSBC issued a "Buy" rating on 12/10/2025
- Guggenheim issued a "Buy" rating on 10/20/2025
- Piper Sandler issued a "Overweight" rating on 10/10/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/15/2025
- BMO Capital issued a "Outperform" rating on 09/12/2025
To track analyst ratings and price targets for ABBVIE, check out Quiver Quantitative's $ABBV forecast page.
ABBVIE Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 16 analysts offer price targets for $ABBV in the last 6 months, with a median target of $250.5.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $230.0 on 01/27/2026
- Michael Yee from UBS set a target price of $240.0 on 01/07/2026
- Terence Flynn from Morgan Stanley set a target price of $269.0 on 12/12/2025
- Rajesh Kumar from HSBC set a target price of $265.0 on 12/10/2025
- David Amsellem from Piper Sandler set a target price of $289.0 on 11/05/2025
- Chris Schott from JP Morgan set a target price of $260.0 on 11/03/2025
- Vamil Divan from Guggenheim set a target price of $242.0 on 10/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
